+ 33 1 46 99 68 20

Laboratoires Delbert signs the Supplier Relations and Purchasing Charter

Jan 2023

Laboratoires Delbert is pleased to announce that it has signed the Responsible Purchasing and Supplier Relations (RFAR) charter.

 

Committed since its creation to responsible approaches with its suppliers, on January 23, 2023 Laboratoires Delbert formalized these commitments by becoming a signatory to the “Responsible Supplier Relations and Purchasing” Charter steered by the Médiateur des Entreprises and the CNA (Conseil National des Achats).

This approach is part of Laboratoires Delbert’s ongoing efforts to integrate environmental and social priorities into its activities. Through this document, Laboratoires Delbert commits to 10 principles for responsible purchasing.

 

10 COMMITMENTS TO RESPONSIBLE PURCHASING

01.

Ensure a responsible financial relationship with suppliers.

02.

Maintain a respectful relationship with all suppliers, favoring the development of collaborative relationships.

03.

Identify and manage reciprocal dependencies with suppliers.

04.

Involve signatory organizations in their industry.

05.

Appreciate all life-cycle costs and impacts.

06.

Integrate environmental and social responsibility issues.

07.

Ensure the territorial responsibility of its organization.

08.

The professionalism and ethics of the purchasing function.

09.

A Purchasing function responsible for overall management of supplier relations.

10.

A “supplier relations” mediator to smooth internal and external relations.

Delbert Pharma awarded Mission-driven company status

Paris, 09/27/2023 Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023. This recognition, the fruit of intense collaborative...

New investment in Laboratoires Delbert

Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company's development in the field of essential and orphan drugs. The historical investors - Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF...